Table 1. Trials included in the analysis, including age eligibility criteria, and status during the reporting period, 1 April 2005–31 March 2007.
| Portfolio/trial acronym | Title | Phase | Age eligibility criteria | Status during 1 April 2005–31 March 2007 |
|---|---|---|---|---|
| Bone sarcoma | ||||
| EURAMOS-1 | A randomised trial of the European and American Osteosarcoma Study Group to optimise treatment strategies for resectable osteosarcoma based on histological response to pre-operative chemotherapy | III | 40 years | Opened September 06 |
| EUROEWINGS 99 (ET 2000 03) | European Ewing Tumour Working Initiatives of National Groups: Ewing Tumour Studies 1999 | III | 50 years | Open |
| Brain and central nervous system | ||||
| LGG 2004 (CNS 2004 03) | Cooperative multicentre study for children and adolescents with low-grade glioma | III | 0–16 years | Open |
| PNET4 (CNS 2003 05) | A prospective randomised controlled trial of hyperfractionated vs conventionally fractionated radiotherapy in standard risk medulloblastoma. | III | 4–22 years | Closed December 2006 |
| SIOP Ependymoma (CNS 1999 04) | SIOP study of combined modality treatment in childhood ependymoma | III | 3–21 years | Open |
| st PNET (CNS 2004 01) | Hyperfractionated Accelerated Radiotherapy (HART) with chemotherapy (Cisplatin, CCNU, Vincristine) for non-pineal supratentorial primitive neuroectodermal tumours | III | 3–18 years | Open |
| Germ cell (male) | ||||
| BEP Continuous infusional bleomycin – TE3 | A randomised phase III toxicity study of day 2,8,15 short (30 m ) vs day 1,2,3 long (72 hours) infusion bleomycin | III | 16–50 years | Open |
| GC 3 (GC 2005 04) | Protocol for the treatment of extracranial germ cell tumours in children and adolescents | III | 0–18 years | Opened May 2005 |
| Leukaemia | ||||
| AML 15 | Medical Research Council working parties on leukaemia in adults and children. Acute myeloid leukaemia trial 15 | III | < 60 years | Open |
| EsPhALL | European Intergroup Study on post induction treatment of Philadelphia positive acute lymphoblastic leukaemia with imatinib | III | < 18 years | Open |
| MRC CLL5 | The value of autografting younger patients with high risk chronic lymphocytic leukaemia (cll). A Randomised Phase III Intergroup Trial | III | >18 years | Open |
| SPIRIT | STI571 Prospective International Randomised Trial. A phase III, prospective randomised comparison of imatinib 400 mg vs imatinib 800 mg vs imatinib plus pegylated interferon in patients with newly-diagnosed chronic myeloid leukaemia. | III | >18 years | Open |
| UKALL XII | Medical Research Council Trial for adult patients with acute lymphoblastic leukaemia Under 56 years of age. To compare related donor transplant vs autologous transplant vs chemotherapy. | III | 15–55 years | Closed to Ph negative patients December 2006 |
| UKALL2003 | Medical Research Council working party on leukaemia in Children. UK National Acute Lymphoblastic Leukaemia (ALL) Trial UKALL 2003 | III | 1–18 years | Open |
| Lymphoma | ||||
| ALCL 99 (NHL 2000 06) | International protocol for the treatment of childhood anaplastic large cell lymphoma | III | 0–22 years | Open |
| BNLI MCD vs FMD | BNLI-Randomised Control Trial of MCD vs FMD in follicular NHL | III | 18–70 years | Closed April 2006 |
| Mantle Cell P3 | A Randomised Controlled Trial of fludarabine/cyclophosphamide combination with or without rituximab in patients with untreated mantle cell lymphoma | III | >18 years | Opened December 2006 |
| PRIMA | A multicentre, phase III, open-label, randomised study in patients with advanced follicular lymphoma evaluating the benefit of maintenance therapy with Rituximab (MabThera) after induction of response with chemotherapy plus Rituximab in comparison with no maintenance therapy | III | >18 years | Closed March 2007 |
| R-CHOP 14 vs 21 | A phase III multicentre Randomised Clinical Trial comparing rituximab with CHOP given every 14 days and rituximab with CHOP given every 21 days for the treatment of patients with newly diagnosed diffuse large B cell non-Hodgkin's lymphoma | III | >18 years | Open |
| BNLI STANFORD V | Protocol for a randomised phase III study of the Stanford V regimen, compared with ABVD for the treatment of advanced Hodgkin's disease | III | 18–60 years | Closed March 2008a |
| Waldenstom's study | A randomised trial of Chlorambucil vs Fludarabine as initial therapy of Waldenström's Macroglobulinaemia and Splenic lymphoma with villous lymphocytes | III | >18 years | Open |
| Watch and Wait | Rituximab in treating patients with newly diagnosed Stage II, Stage III, or Stage IV Follicular Non-Hodgkin's Lymphoma | III | >18 years | Open |
Abbreviations: BNLI: British National Lymphoma Investigation; CCNU: Lomustine; FMD: Fludarabine, Mitoxantrone and Dexamethasone; MCD: mitoxantrone, chlorambucil and dexamethasone; SIOP: International Society of Paediatric Oncology.
a
This trial was suspended prior to closing.